Skip to main content

ANOTHER BIG PHARMA DEAL

NOVARTIS BUYS GSK's CANCER DRUG
Global pharma major Novartis will acquire GlaxoSmithKline plc's (GSK) cancer drugs portfolio for USD 16 billion and sell its vaccines business in return for USD 7.1 billion, apart from forming a joint venture for the consumer healthcare business in a three-part transaction. In separate statements, the two companies said they will combine Novartis' over-the-counter (OTC)) division with GSK's consumer business, creating a new world-leading consumer healthcare business with USD 10 billion in annual sales. UK-headquartered GSK will have majority control with an equity interest of 63.5 per cent in the venture. Novartis, based in Basel, Switzerland, agreed to acquire GSK's oncology products for USD 14.5 billion and up to USD 1.5 billion contingent on a development milestone. Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline. On the other hand, Novartis will divest its vaccines business, excluding flu, to GSK, for USD 7.1 billion plus royalties. The upfront payment is USD 5.25 billion and up to USD 1.8 billion is in milestones. Separately, Novartis said it has initiated a separate sales process for its flu business as part of a value maximisation strategy in the context of the portfolio review. "The transactions mark a transformational moment for Novartis," CEO Joseph Jimenez said. "They focus the company on leading businesses with innovation power and global scale. They also improve our financial strength and are expected to add to our growth rates and margins immediately." Stating that the deal is a win-win for both, GSK Chief Executive Officer Sir Andrew Witty said: "This proposed three-part transaction accelerates our strategy to generate sustainable, broadly sourced sales growth and improve long-term earnings." The Novartis OTC portfolio is highly complementary to GSK's and has brands such as Voltaren, Excedrin, Otrivin and Theraflu, he added. "Together, we will create the world's premier OTC business with clear opportunities to accelerate revenue growth," he said. The Swiss pharma major separately agreed to sell its animal health division to Lilly for about USD 5.4 billion. This transaction is the result of a competitive process, which upon completion would create a leading animal health business under Lilly's ownership and would optimise the value of the asset in the interest of Novartis shareholders, the company said. 
The joint venture of Novartis OTC and GSK Consumer Healthcare would have leading positions in four key OTC categories - wellness, oral health, nutrition and skin health, the companies said. Almost half of the venture's sales would be derived from brands larger than USD 300 million in annual revenue. The geographic footprint would span all regions, with scale and commercial presence in the developed world as well as in key emerging markets such as Brazil, China, Mexico and Russia. Stressing that opportunities to build greater scale and combine high-quality assets in vaccines and consumer healthcare are scarce, Sir Witty said: "With this transaction, we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders." GSK said its shareholders would receive 4 billion pounds capital return funded by net cash transaction proceeds, expected to be delivered via a B share scheme. The proposed transaction would increase GSK's annual revenue by 1.3 billion pounds to 26.9 billion pounds on a 2013 pro forma basis, it added. 

Comments

Popular posts from this blog

JIO TARIFF CICK FOR TELECOM STOCKS

Telecom stocks today surged up to 8 per cent after the recent increase in Reliance Jio tariffs, which is largely seen as positive for the sector. Shares of Bharti Airtel jumped 4.99 per cent to close at Rs 497.50 on BSE. Bharti Airtel was the biggest gainer among the 30-share index components. The scrip of Idea Cellular soared 7.74 per cent to end at Rs 98.15 and Reliance Communications zoomed 7.60 per cent to Rs 17.70. Reliance Jio made its service dearer by about 15 per cent for its popular 84-day plan at Rs 459 from October 19, under which subscribers get 1GB 4G data at high speed per day. The company restructured its various schemes by reducing their validity period. The recent increase in Reliance Jio tariffs will increase its average revenue per user by up to 20 per cent and is a positive for the telecom sector, which is seeing a rapid consolidation, says a Philip Capital report. Established telecom sector players have seen huge reduction in their margins. Idea Cellular and Reli…

INVESTORS RICHER BY Rs. 25 LAKH CRORES IN SAMVAT 2073

Stock markets ended on a flat note on Wednesday, just below their record highs, but finished Samvat 2073 with robust gains of over 16 per cent. Equities added over Rs 25 lakh crore to investors' wealth this Samvat year. The benchmark Sensex has gained 4642.84 points, or 16.61 per cent, in the Hindu Samvat year 2073, while the broader NSE Nifty surged 1572.85 points, or 18.20 per cent during this period.
Small loss in last session
In the last session of the Samvat 2073 on Wednesday, the 50-share Nifty fell by 23.60 points or 0.23 per cent to close at 10,210.85 after moving between 10,175.75 and 10,236.45. The Sensex resumed lower at 32,518.56 and fell further to a low of 32,462.85 before ending at 32,584.35, down 24.81 points or 0.08 per cent. Investors adopted a cautious approach ahead of the long Diwali weekend, while a weak rupee too affected sentiment, brokers said.
- Axis Bank emerged as the worst performer among Sensex components, tumbling 9.52 per cent following a spike in ba…

BIRLAS ENTER TOP LEAGUE WITH $50 BILLION M CAP

The Aditya Birla group has entered the top valuation league with a market cap of over USD 50 billion post listing of financial services arm Aditya Birla Capital (ABCL), but Tatas remain on top with over USD 132 billion.
The combined market valuation of the Kumar Mangalam Birla-led listed companies stood at Rs 3,42,354.87 crore (USD 53.5 billion) at the end of Friday's trade.
Among various listed companies of the group, UltraTech Cement's valuation stood at Rs 1,10,097.70 crore at the end of Friday's trade while that of Grasim Industries was Rs 76,881.73 crore.
The newly-listed Aditya Birla Capital's market capitalisation was over Rs 55,000 crore, Hindalco (Rs 54,607.09 crore), Idea Cellular (Rs 32,064.91 crore), Aditya Birla Fashion and Retail (Rs 13,155.73 crore) and Aditya Birla Money (Rs 547.71 crore).
Among Indian conglomerates, the Tata group remains on the top in terms of total valuation of listed firms with about Rs 8,46,567 crore (USD 132.5 billion).
There are 29 pu…